The prognostic role of p53 mutations in metastatic colorectal cancer: a systematic review and meta-analysis

Alessandro Ottaiano is an Oncologist working at the SSD-Innovative Therapies for Abdominal Metastases at the Department of Abdominal Oncology, National Cancer Institute of Naples (IRCCS “G. Pascale”). In 1999, he earned his Medical Degree from the "Federico II" University of Naples, followed by his specialization in Oncology in 2003. Prior to obtaining his degree, he dedicated four years as an intern at the Immunology Laboratory of the Department of Cellular Biology and Pathology, Faculty of Medicine and Surgery, University of Naples "Federico II," studying the modulation of NK cell functions against tumors by MHC class I molecules. Dr. Ottaiano joined the National Cancer Institute of Naples (IRCCS “G. Pascale”) in 2004 as an Assistant Professor, where he initiated his research pursuits in translational clinical research focused on innovative therapies, biomarkers, and genetics of several cancers, including sarcoma, melanoma, neuroendocrine tumors, cholangiocarcinoma, and colorectal cancer. He has conducted meta-analyses on therapy for neuroendocrine, pancreatic, and colorectal cancers. Dr. Ottaiano has published over 160 papers, attaining an H-index of 29 according to SCOPUS. He heads and participates in several research projects. Currently, Dr. Ottaiano's endeavors are dedicated to conceiving and executing pioneering translational clinical studies that aim to enhance our understanding of the genetic and immunological mechanisms underlying gastrointestinal tract tumors.

留言 (0)

沒有登入
gif